

# Activity of convalescent and vaccine serum against SAR

Nature

602, 682-688

DOI: [10.1038/s41586-022-04399-5](https://doi.org/10.1038/s41586-022-04399-5)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Omicron, the great escape artist. <i>Nature Reviews Immunology</i> , 2022, 22, 75-75.	10.6	87
4	Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. <i>Nature Medicine</i> , 2022, 28, 496-503.	15.2	215
6	Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants. <i>Nature</i> , 2022, 603, 919-925.	13.7	146
8	Identification of human and mosquito receptors for alphaviruses. <i>Nature</i> , 2022, , .	13.7	1
9	SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. <i>Cell</i> , 2022, 185, 847-859.e11.	13.5	590
11	SARS-CoV-2 Transmission and Prevention in the Era of the Delta Variant. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 267-293.	1.9	10
12	Substantial immune response in Omicron infected breakthrough and unvaccinated individuals against SARS-CoV-2 variants of concern. <i>Journal of Infection</i> , 2022, 84, e80-e81.	1.7	13
16	Cryo-EM structure of the SARS-CoV-2 Omicron spike. <i>Cell Reports</i> , 2022, 38, 110428.	2.9	82
17	Post-recovery enhancement of anti-variant neutralisation after severe COVID-19. <i>Lancet Microbe</i> , The, 2022, 3, e330-e331.	3.4	3
18	SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine. <i>Science Immunology</i> , 2022, 7, eabn8590.	5.6	88
19	Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients. <i>Science Immunology</i> , 2022, 7, eabo2202.	5.6	337
21	A tabulated summary of the evidence on humoral and cellular responses to the SARS-CoV-2 Omicron VOC, as well as vaccine efficacy against this variant.. <i>Immunology Letters</i> , 2022, 243, 38-43.	1.1	18
22	Development of SARS-CoV-2 variant protein microarray for profiling humoral immunity in vaccinated subjects. <i>Biosensors and Bioelectronics</i> , 2022, 204, 114067.	5.3	9
24	Levels of SARS-CoV-2 Antibodies Among Fully-Vaccinated Individuals With Delta or Omicron Variant Breakthrough Infections: A Prospective Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4
25	Sequentially immune-induced antibodies could cross-neutralize SARS-CoV-2 variants. <i>Animal Models and Experimental Medicine</i> , 2022, 5, 89-93.	1.3	4
26	Molecular basis of receptor binding and antibody neutralization of Omicron. <i>Nature</i> , 2022, 604, 546-552.	13.7	135
27	Successive Pandemic Waves with Different Virulent Strains and the Effects of Vaccination for SARS-CoV-2. <i>Vaccines</i> , 2022, 10, 343.	2.1	4
28	Neutralization of SARS-CoV-2 Variants by rVSV-Î³G-Spike-Elicited Human Sera. <i>Vaccines</i> , 2022, 10, 291.	2.1	19

#	ARTICLE	IF	CITATIONS
29	SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern. <i>ELife</i> , 2022, 11, .	2.8	26
33	Elevated neutralization of Omicron with sera of COVID-19 recovered and breakthrough cases vaccinated with Covaxin than two dose naïve vaccinees. <i>Journal of Infection</i> , 2022, 84, 834-872.	1.7	13
35	Computation of Antigenicity Predicts SARS-CoV-2 Vaccine Breakthrough Variants. <i>Frontiers in Immunology</i> , 2022, 13, 861050.	2.2	8
36	Defining the risk of SARS-CoV-2 variants on immune protection. <i>Nature</i> , 2022, 605, 640-652.	13.7	117
39	Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant. <i>BMC Medicine</i> , 2022, 20, 102.	2.3	67
40	A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant. <i>ACS Infectious Diseases</i> , 2022, 8, 825-840.	1.8	3
41	Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. <i>Cell</i> , 2022, 185, 1549-1555.e11.	13.5	59
45	Durability and Cross-Reactivity of SARS-CoV-2 mRNA Vaccine in Adolescent Children. <i>Vaccines</i> , 2022, 10, 492.	2.1	9
46	Advances in the Omicron variant development. <i>Journal of Internal Medicine</i> , 2022, 292, 81-90.	2.7	85
47	The SARS-CoV-2 Omicron Variant Does Not Have Higher Nasal Viral Loads Compared to the Delta Variant in Symptomatic and Asymptomatic Individuals. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0013922.	1.8	28
48	Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. <i>Nature Medicine</i> , 2022, 28, 1042-1049.	15.2	61
49	Innovative adjuvant augments potency of a SARS-CoV-2 subunit vaccine. <i>Cell Research</i> , 2022, 32, 331-332.	5.7	1
50	Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection. <i>New England Journal of Medicine</i> , 2022, 386, 1764-1766.	13.9	77
52	Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. <i>Nature Medicine</i> , 2022, 28, 1297-1302.	15.2	235
53	SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals. <i>Cell Host and Microbe</i> , 2022, 30, 880-886.e4.	5.1	80
54	Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2. <i>Nature Medicine</i> , 2022, 28, 1491-1500.	15.2	239
56	SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies. <i>Science Translational Medicine</i> , 2022, 14, eabn8543.	5.8	75
57	Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant. <i>Immunity</i> , 2022, 55, 1096-1104.e4.	6.6	42

#	ARTICLE	IF	CITATIONS
59	Omicron™s binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals. IScience, 2022, 25, 104076.	1.9	25
60	Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants. Med, 2022, 3, 249-261.e4.	2.2	56
61	Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern. EBioMedicine, 2022, 79, 103997.	2.7	29
62	Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections. Emerging Infectious Diseases, 2022, 28, 1050-1052.	2.0	11
63	Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines. EBioMedicine, 2022, 79, 103986.	2.7	23
64	Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals. , 2022, 19, 588-601.		27
65	Structures of Omicron spike complexes and implications for neutralizing antibody development. Cell Reports, 2022, 39, 110770.	2.9	47
67	Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test. , 2022, 1, .		5
68	Structural insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction. Cell Research, 2022, 32, 593-595.	5.7	55
69	COVID-19: Omicron “ the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2. Microbial Biotechnology, 2022, 15, 1927-1939.	2.0	41
70	Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years. Lancet Regional Health - Europe, The, 2022, 17, 100385.	3.0	18
71	The Evolution and Biology of SARS-CoV-2 Variants. Cold Spring Harbor Perspectives in Medicine, 2022, 12, a041390.	2.9	110
72	Delphi Survey for COVID-19 Vaccination in Korean Children Between 5 and 11 Years Old. Pediatric Infection and Vaccine, 2022, 29, 37.	0.1	2
73	Safety and Cross-Reactive Immune Response Against the Omicron Variant of a Third Dose of CoronaVac, and Immune Persistence of Primary Immunization in Healthy Children and Adolescents: Interim Results from a Double-Blind, Randomised, Placebo-Controlled Phase 2 Clinical Trial. SSRN Electronic Journal, 0, .	0.4	0
74	Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. BioDrugs, 2022, 36, 231-323.	2.2	24
75	Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants. Frontiers in Immunology, 2022, 13, 804945.	2.2	12
76	Longitudinal Analysis of Coronavirus-Neutralizing Activity in COVID-19 Patients. Viruses, 2022, 14, 882.	1.5	3
78	Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants. Biomedicines, 2022, 10, 996.	1.4	3

#	ARTICLE	IF	CITATIONS
79	SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance. <i>Frontiers in Immunology</i> , 2022, 13, 877101.	2.2	74
80	Vaccination versus SARS-CoV-2 Omicron: three vaccine doses win the battle. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 140.	7.1	2
81	Application of animal models to compare and contrast the virulence of current and future potential SARS-CoV-2 variants. <i>Biosafety and Health</i> , 2022, 4, 154-160.	1.2	3
82	SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients – A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	24
83	Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine. <i>JAMA Network Open</i> , 2022, 5, e2210780.	2.8	27
84	SARS-CoV-2 variants – Evolution, spike protein, and vaccines. <i>Biomedical Journal</i> , 2022, 45, 573-579.	1.4	26
85	Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-19.	1.4	20
86	Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant. <i>MedComm</i> , 2022, 3, e143.	3.1	3
87	Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2118312119.	3.3	86
88	SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies. <i>Cell Host and Microbe</i> , 2022, 30, 1103-1111.e6.	5.1	38
89	T cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine. <i>Journal of Medical Virology</i> , 2022, 94, 3998-4004.	2.5	20
90	Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. <i>Cell Host and Microbe</i> , 2022, 30, 1077-1083.e4.	5.1	132
91	Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants. <i>EBioMedicine</i> , 2022, 80, 104025.	2.7	13
92	Antibody-mediated neutralization of SARS-CoV-2. <i>Immunity</i> , 2022, 55, 925-944.	6.6	74
93	Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. <i>Nature Communications</i> , 2022, 13, 2670.	5.8	108
94	Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. <i>Vaccine</i> , 2022, 40, 3621-3632.	1.7	15
95	BNT162b2-induced memory T cells respond to the Omicron variant with preserved polyfunctionality. <i>Nature Microbiology</i> , 2022, 7, 909-917.	5.9	41
96	Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. <i>Nature</i> , 2022, 607, 119-127.	13.7	174

#	ARTICLE	IF	CITATIONS
97	Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization. <i>Transfusion</i> , 2022, 62, 1347-1354.	0.8	9
98	PARIS and SPARTA: Finding the Achilles' Heel of SARS-CoV-2. <i>MSphere</i> , 2022, 7, e0017922.	1.3	25
100	Relevant of neutralizing antibody during SARS-CoV-2 infection and their therapeutic usage. <i>Molecular Biology Reports</i> , 2022, 49, 10137-10140.	1.0	6
103	Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial. <i>EBioMedicine</i> , 2022, 80, 104073.	2.7	28
104	The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants. <i>Immunity</i> , 2022, 55, 1316-1326.e4.	6.6	38
105	Humoral and cellular immune memory to four COVID-19 vaccines. <i>Cell</i> , 2022, 185, 2434-2451.e17.	13.5	289
106	COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 104457.	1.9	8
107	Omicron Infection Evokes Cross-Protection against SARS-CoV-2 Variants in Vaccinees. <i>Vaccines</i> , 2022, 10, 808.	2.1	7
108	SARS-CoV-2 transmission, persistence of immunity, and estimates of Omicron's impact in South African population cohorts. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	36
110	Association of Frailty, Age, and Biological Sex With Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine-Induced Immunity in Older Adults. <i>Clinical Infectious Diseases</i> , 2022, 75, S61-S71.	2.9	27
111	The SARS-CoV-2 Variant Omicron Is Able to Escape Vaccine-Induced Humoral Immune Responses, but Is Counteracted by Booster Vaccination. <i>Vaccines</i> , 2022, 10, 794.	2.1	5
114	Humoral immune response to authentic circulating severe acute respiratory syndrome coronavirus 2 variants elicited by booster vaccination with distinct receptor-binding domain subunits in mice. <i>Journal of Medical Virology</i> , 0, , .	2.5	4
115	Recent insights into SARS-CoV-2 omicron variant. <i>Reviews in Medical Virology</i> , 2023, 33, .	3.9	29
116	Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) Serology in the Vaccination Era and Post Booster Vaccination. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
118	Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant. <i>Clinical Microbiology Reviews</i> , 2022, 35, .	5.7	35
119	Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees. <i>Nature Communications</i> , 2022, 13, .	5.8	20
120	Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants. <i>Clinical Infectious Diseases</i> , 2023, 76, e240-e249.	2.9	11
121	OMICRON: Virology, immunopathogenesis, and laboratory diagnosis. <i>Journal of Gene Medicine</i> , 2022, 24, .	1.4	33

#	ARTICLE	IF	CITATIONS
123	Therapeutics to tackle Omicron outbreak. <i>Immunotherapy</i> , 2022, 14, 833-838.	1.0	22
124	Concerns on the Effectiveness of Current COVID-19 Vaccines. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	0
125	Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters. <i>Nature Microbiology</i> , 2022, 7, 1252-1258.	5.9	20
126	Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	14
128	Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California. <i>Nature Medicine</i> , 2022, 28, 1933-1943.	15.2	243
129	Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys. <i>Vaccine</i> , 2022, 40, 4231-4241.	1.7	11
130	Asymptomatic or Symptomatic SARS-CoV-2 Infection Plus Vaccination Confers Increased Adaptive Immunity to Variants of Concern of SARS-CoV-2 Including Omicron. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
131	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	59
132	A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding. <i>Cell Research</i> , 2022, 32, 862-865.	5.7	8
133	A broad and potent neutralization epitope in SARS-related coronaviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	34
134	The humoral response and antibodies against SARS-CoV-2 infection. <i>Nature Immunology</i> , 2022, 23, 1008-1020.	7.0	84
135	Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
137	Wastewater surveillance allows early detection of SARS-CoV-2 omicron in North Rhine-Westphalia, Germany. <i>Science of the Total Environment</i> , 2022, 846, 157375.	3.9	13
138	The T Cell Epitope Landscape of SARS-CoV-2 Variants of Concern. <i>Vaccines</i> , 2022, 10, 1123.	2.1	4
139	SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns. <i>Cell Host and Microbe</i> , 2022, 30, 1231-1241.e6.	5.1	55
140	A booster dose of Delta—Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	42
141	SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. <i>Nature Microbiology</i> , 2022, 7, 1161-1179.	5.9	352
142	Real-world Association Between mRNA Vaccination and Infection From the Omicron Strain of SARS-CoV-2: A Population-level Analysis. , 2022, , 100010.		1

#	ARTICLE	IF	CITATIONS
143	<scp>COVID</scp>â€19 and plasma cells: Is there longâ€lived protection?*. Immunological Reviews, 2022, 309, 40-63.	2.8	26
144	The Host Response to Influenza A Virus Interferes with SARS-CoV-2 Replication during Coinfection. Journal of Virology, 2022, 96, .	1.5	23
145	Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies. EBioMedicine, 2022, 82, 104158.	2.7	128
146	Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study. EClinicalMedicine, 2022, 50, 101529.	3.2	3
147	Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	96
148	Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. Science Immunology, 2022, 7, .	5.6	170
149	Immune Evasion by the Highly Mutated SARS-CoV-2 Omicron Variant. Infection and Drug Resistance, 0, Volume 15, 4013-4027.	1.1	4
150	Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study. EClinicalMedicine, 2022, 51, 101576.	3.2	14
151	Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review. International Journal of Biological Sciences, 2022, 18, 4629-4641.	2.6	24
152	Robust neutralizing antibody responses after single-dose BNT162b2 vaccination at long intervals from prior SARS-CoV-2 infection and ceiling effect with repeated vaccination. Journal of Infection, 2022, , .	1.7	3
155	Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination. Vaccines, 2022, 10, 1163.	2.1	4
156	Reduced binding activity of vaccine serum to omicron receptor-binding domain. Frontiers in Immunology, 0, 13, .	2.2	1
157	SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study. Annals of the Rheumatic Diseases, 2022, 81, 1585-1593.	0.5	12
158	Subâ€lineages of the SARSâ€CoVâ€2 Omicron variants:â€Characteristics and prevention. MedComm, 2022, 3, .	3.1	15
160	Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways. IScience, 2022, 25, 104914.	1.9	5
161	Durability of Heterologous and Homologous COVID-19 Vaccine Boosts. JAMA Network Open, 2022, 5, e2226335.	2.8	42
162	A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern. Journal of Virology, 2022, 96, .	1.5	14
163	SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from Reinfection with Antigenically Similar SARS-CoV-2 Variants. MBio, 2022, 13, .	1.8	6



#	ARTICLE	IF	CITATIONS
165	mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant. <i>Communications Biology</i> , 2022, 5, .	2.0	15
167	Structural analysis of Spike proteins from SARS-CoV-2 variants of concern highlighting their functional alterations. <i>Future Virology</i> , 2022, 17, 723-732.	0.9	7
168	Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections. <i>Nature Communications</i> , 2022, 13, .	5.8	54
169	Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein. <i>Nature Communications</i> , 2022, 13, .	5.8	12
170	Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine. <i>Cell Reports Medicine</i> , 2022, 3, 100716.	3.3	16
171	Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COVS vaccines. <i>Journal of Medical Virology</i> , 2022, 94, 5678-5690.	2.5	16
172	Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine Doses. <i>Vaccines</i> , 2022, 10, 1237.	2.1	2
173	Antibody response against SARS-CoV-2 variants of concern in children infected with pre-Omicron variants: An observational cohort study. <i>EBioMedicine</i> , 2022, 83, 104230.	2.7	11
174	Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine. <i>EBioMedicine</i> , 2022, 83, 104196.	2.7	26
175	Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination. <i>IScience</i> , 2022, 25, 104886.	1.9	5
176	Omicron (B.1.1.529) - A new heavily mutated variant: Mapped location and probable properties of its mutations with an emphasis on S-glycoprotein. <i>International Journal of Biological Macromolecules</i> , 2022, 219, 980-997.	3.6	28
177	Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113522.	2.5	56
178	Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages. <i>Cell Discovery</i> , 2022, 8, .	3.1	13
179	Cross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines. <i>International Journal of Biological Sciences</i> , 2022, 18, 4781-4791.	2.6	5
180	Differences Between Omicron Infections and Fever Outpatients: Comparison of Clinical Manifestations and Initial Routine Hematology Indicators. <i>Infection and Drug Resistance</i> , 0, Volume 15, 5111-5120.	1.1	2
181	Antibody Response against Circulating Omicron Variants 8 Months after the Third Dose of mRNA Vaccine. <i>Vaccines</i> , 2022, 10, 1512.	2.1	3
182	Covid-19 Vaccines – Immunity, Variants, Boosters. <i>New England Journal of Medicine</i> , 2022, 387, 1011-1020.	13.9	266
183	Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity. <i>Nature Communications</i> , 2022, 13, .	5.8	42

#	ARTICLE	IF	CITATIONS
184	The neutralization of B.1.617.1 and B.1.1.529 sera from convalescent patients and BBIBP-CorV vaccines. <i>IScience</i> , 2022, 25, 105016.	1.9	2
185	Neutralization effect of plasma from vaccinated COVID-19 convalescents on SARS-CoV-2 Omicron variants. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
189	Molecular Insights into Striking Antibody Evasion of SARS-CoV-2 Omicron Variant. <i>Chinese Physics Letters</i> , 2022, 39, 108701.	1.3	3
190	Asymptomatic or symptomatic SARS-CoV-2 infection plus vaccination confers increased adaptive immunity to variants of concern. <i>IScience</i> , 2022, 25, 105202.	1.9	3
191	Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2. <i>Cell Reports Medicine</i> , 2022, 3, 100743.	3.3	19
192	Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
193	Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2. <i>Emerging Microbes and Infections</i> , 2022, 11, 2275-2287.	3.0	48
194	The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: Results of a non-randomized clinical trial. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	16
195	Development of variant-agnostic proof severe acute respiratory syndrome coronavirus 2, pan-coronavirus, and pan-beta-coronavirus vaccines. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	12
196	Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection. <i>Med</i> , 2022, 3, 838-847.e3.	2.2	26
197	Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies. <i>Cell Discovery</i> , 2022, 8, .	3.1	10
198	SARS-CoV-2 Omicron Variant of Concern: Everything You Wanted to Know about Omicron but Were Afraid to Ask. <i>Yonsei Medical Journal</i> , 2022, 63, 977.	0.9	7
199	Omicron variant of SARS-CoV-2 infection elicits cross-protective immunity in people who received boosters or infected with variant strains. <i>International Journal of Immunopathology and Pharmacology</i> , 2022, 36, 039463202211330.	1.0	2
201	Evaluation of immunoprotection against coronavirus disease 2019: Novel variants, vaccine inoculation, and complications. <i>Journal of Pharmaceutical Analysis</i> , 2023, 13, 1-10.	2.4	1
202	Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster. <i>IScience</i> , 2022, 25, 105465.	1.9	2
204	Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	3
205	ColdZyme® protects airway epithelia from infection with BA.4/5. <i>Respiratory Research</i> , 2022, 23, .	1.4	7
206	SARS-CoV-2 evolves to reduce but not abolish neutralizing action. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	6

#	ARTICLE	IF	CITATIONS
207	Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study. <i>International Journal of Infectious Diseases</i> , 2022, 125, 195-208.	1.5	21
208	Cartography of SARS-CoV-2 variants based on the susceptibility to therapeutic monoclonal antibodies. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1
210	The rapid emergence of multiple sublineages of Omicron (B.1.1.529) variant: Dynamic profiling via molecular phylogenetics and mutational landscape studies. <i>Journal of Infection and Public Health</i> , 2022, 15, 1234-1258.	1.9	14
211	Bioinformatic Analysis of B- and T-cell Epitopes from SARS-CoV-2 Structural Proteins and their Potential Cross-reactivity with Emerging Variants and other Human Coronaviruses. <i>Archives of Medical Research</i> , 2022, 53, 694-710.	1.5	5
212	An electrochemical biosensor for SARS-CoV-2 detection via its papain-like cysteine protease and the protease inhibitor screening. <i>Chemical Engineering Journal</i> , 2023, 452, 139646.	6.6	23
213	Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents. <i>Nature Communications</i> , 2022, 13, .	5.8	3
214	The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What. <i>Vaccines</i> , 2022, 10, 1924.	2.1	8
215	Homologous and heterologous booster vaccinations of S-268019-b, a recombinant S protein-based vaccine with a squalene-based adjuvant, enhance neutralization breadth against SARS-CoV-2 Omicron subvariants in cynomolgus macaques. <i>Vaccine</i> , 2022, 40, 7520-7525.	1.7	4
216	Cross-reactive SARS-CoV-2 epitope targeted across donors informs immunogen design. <i>Cell Reports Medicine</i> , 2022, 3, 100834.	3.3	2
218	Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies. <i>Cell Reports Medicine</i> , 2022, 3, 100850.	3.3	32
219	Reduced neutralization against Delta, Gamma, Mu, and Omicron BA.1 variants of SARS-CoV-2 from previous non-Omicron infection. <i>Medical Microbiology and Immunology</i> , 2023, 212, 25-34.	2.6	4
220	The impact of vaccination on patients with COVID-19 during the wave of Omicron in Shanghai. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
221	A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein. <i>Cell Research</i> , 2022, 32, 1068-1085.	5.7	27
222	An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
223	Systematic review of primary and booster COVID-19 sera neutralizing ability against SARS-CoV-2 omicron variant. <i>Npj Vaccines</i> , 2022, 7, .	2.9	10
224	Effect of Previous COVID-19 Vaccination on Humoral Immunity 3 Months after SARS-CoV-2 Omicron Infection and Booster Effect of a Fourth COVID-19 Vaccination 2 Months after SARS-CoV-2 Omicron Infection. <i>Viruses</i> , 2022, 14, 2458.	1.5	8
225	Pathogenesis and Preventive Tactics of Immune-Mediated Non-Pulmonary COVID-19 in Children and Beyond. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14157.	1.8	3
226	SARS-CoV-2 Omicron BA.1 and BA.2 are attenuated in rhesus macaques as compared to Delta. <i>Science Advances</i> , 2022, 8, .	4.7	28

#	ARTICLE	IF	CITATIONS
228	Hepatic dysfunctions in COVID-19 patients infected by the omicron variant of SARS-CoV-2. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
229	Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: real-world study in Jilin Province, China. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	12
230	Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies. <i>Journal of Infection and Public Health</i> , 2023, 16, 4-14.	1.9	105
231	A novel plant-made monoclonal antibody enhances the synergetic potency of an antibody cocktail against the SARS-CoV-2 Omicron variant. <i>Plant Biotechnology Journal</i> , 2023, 21, 549-559.	4.1	8
232	Severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) serology in the vaccination era and post booster vaccination. <i>Journal of Clinical Virology Plus</i> , 2023, 3, 100130.	0.4	0
233	A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
234	Modelling optimal lockdowns with waning immunity. <i>Economic Theory</i> , 2024, 77, 197-234.	0.5	7
235	Simultaneous measurement of multiple variant-specific SARS-CoV-2 neutralizing antibodies with a multiplexed flow cytometric assay. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
236	Advances in Next-Generation Coronavirus Vaccines in Response to Future Virus Evolution. <i>Vaccines</i> , 2022, 10, 2035.	2.1	3
237	Vaccination with the Omicron spike RBD boosts broadly neutralizing antibody levels and confers sustained protection even after acquiring immunity to the original antigen. <i>International Immunology</i> , 2023, 35, 197-207.	1.8	4
238	Immune evasion of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2); molecular approaches. <i>Molecular Immunology</i> , 2023, 156, 10-19.	1.0	3
239	Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	13
242	SARS-CoV-2 viral load and shedding kinetics. <i>Nature Reviews Microbiology</i> , 0, , .	13.6	57
243	Long-term outcomes of COVID-19 convalescents: An 18.5-month longitudinal study in Wuhan. <i>International Journal of Infectious Diseases</i> , 2023, 127, 85-92.	1.5	10
244	Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern. <i>Npj Vaccines</i> , 2022, 7, .	2.9	9
245	SARS-CoV-2 antibody responses post-vaccination in UK healthcare workers with pre-existing medical conditions: a cohort study. <i>BMJ Open</i> , 2022, 12, e066766.	0.8	2
246	The SARS-CoV-2 spike S375F mutation characterizes the Omicron BA.1 variant. <i>IScience</i> , 2022, 25, 105720.	1.9	27
247	Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses. <i>Nature Communications</i> , 2022, 13, .	5.8	17

#	ARTICLE	IF	CITATIONS
248	COVID-19 vaccination boosts the potency and breadth of the immune response against SARS-CoV-2 among recovered patients in Wuhan. <i>Cell Discovery</i> , 2022, 8, .	3.1	3
249	Evaluation of antibody response to SARS-CoV-2 variants after 2 doses of mRNA COVID-19 vaccine in a correctional facility. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	3
250	Immune responses related to the immunogenicity and reactogenicity of COVID-19 mRNA vaccines. <i>International Immunology</i> , 2023, 35, 213-220.	1.8	6
251	Neutralizing and enhancing antibodies against SARS-CoV-2. <i>Inflammation and Regeneration</i> , 2022, 42, .	1.5	6
252	BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants. <i>Nature Communications</i> , 2022, 13, .	5.8	42
253	Population-Based Analysis of the Immunoglobulin G Response to Different COVID-19 Vaccines in Brazil. <i>Vaccines</i> , 2023, 11, 21.	2.1	0
254	The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages. <i>Virologica Sinica</i> , 2022, 37, 786-795.	1.2	12
255	Recent developments in the immunopathology of COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2023, 78, 369-388.	2.7	33
257	Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants. <i>MBio</i> , 2023, 14, .	1.8	14
258	Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization. <i>IScience</i> , 2023, 26, 105969.	1.9	6
259	Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
260	Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA.1 attenuation. <i>Nature</i> , 2023, 615, 143-150.	13.7	52
261	Respiratory Bacterial and Fungal Superinfections During the Third Surge of the COVID-19 Pandemic in Iran. <i>Microbial Drug Resistance</i> , 2023, 29, 104-111.	0.9	1
262	Comprehensive Comparison of Seven SARS-CoV-2-Specific Surrogate Virus Neutralization and Anti-Spike IgG Antibody Assays Using a Live-Virus Neutralization Assay as a Reference. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	16
264	RAMIHM generates fully human monoclonal antibodies by rapid mRNA immunization of humanized mice and BCR-seq. <i>Cell Chemical Biology</i> , 2023, 30, 85-96.e6.	2.5	3
266	Humoral immunity for durable control of SARS-CoV-2 and its variants. <i>Inflammation and Regeneration</i> , 2023, 43, .	1.5	6
267	Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2. <i>Biomedical Journal</i> , 2023, 46, 70-80.	1.4	8
268	An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals. <i>IScience</i> , 2023, 26, 105949.	1.9	1

#	ARTICLE	IF	CITATIONS
269	Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients. <i>American Journal of Transplantation</i> , 2023, 23, 423-428.	2.6	8
270	Longitudinal observation of viral load in patients infected with Omicron variant and its relationship with clinical symptoms. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	1
271	Comparison of humoral immunogenicity in solid organ transplant recipients after third-dose mRNA vaccine with homologous or heterologous schedules: An observational study. <i>Journal of Clinical Virology</i> , 2023, 159, 105374.	1.6	3
272	Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy. <i>Multiple Sclerosis and Related Disorders</i> , 2023, 70, 104486.	0.9	6
273	Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants. <i>Genome Medicine</i> , 2022, 14, .	3.6	12
274	Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques. <i>JCI Insight</i> , 2023, 8, .	2.3	11
275	A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants. <i>Science China Life Sciences</i> , 2023, 66, 1818-1830.	2.3	11
277	Clinical Outcomes of SARS-CoV-2 Breakthrough Infections in Liver Transplant Recipients during the Omicron Wave. <i>Viruses</i> , 2023, 15, 297.	1.5	6
278	Exploring epidemic voluntary vaccinating behavior based on information-driven decisions and benefit-cost analysis. <i>Applied Mathematics and Computation</i> , 2023, 447, 127905.	1.4	1
279	Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update. <i>Process Biochemistry</i> , 2023, 127, 66-81.	1.8	9
280	Clinical and upper airway characteristics of 3715 patients with the Omicron variant of SARS-Cov-2 in Changchun, China. <i>Journal of Infection and Public Health</i> , 2023, 16, 422-429.	1.9	11
281	Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies. <i>Blood Advances</i> , 2023, 7, 5691-5697.	2.5	4
282	Early Introduction and Community Transmission of SARS-CoV-2 Omicron Variant, New York, New York, USA. <i>Emerging Infectious Diseases</i> , 2023, 29, 371-380.	2.0	1
284	Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination. <i>Journal of Virology</i> , 2023, 97, .	1.5	5
285	Intra-Host Evolution Provides for the Continuous Emergence of SARS-CoV-2 Variants. <i>MBio</i> , 2023, 14, .	1.8	5
286	Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies. <i>Nature Communications</i> , 2023, 14, .	5.8	87
287	An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	2
288	Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. <i>Immunity</i> , 2023, 56, 669-686.e7.	6.6	43

#	ARTICLE	IF	CITATIONS
289	Model-Based Optimization of Vaccination Strategies in Different Phases of Pandemic Virus Spread. <i>Lecture Notes in Electrical Engineering</i> , 2023, , 185-208.	0.3	0
290	A Beta Strain-Based Spike Glycoprotein Vaccine Candidate Induces Broad Neutralization and Protection against SARS-CoV-2 Variants of Concern. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	1
291	Monovalent and trivalent VSV-based COVID-19 vaccines elicit neutralizing antibodies and CD8+ T cells against SARS-CoV-2 variants. <i>IScience</i> , 2023, 26, 106292.	1.9	1
292	SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination. <i>Bone Marrow Transplantation</i> , 2023, 58, 567-580.	1.3	12
293	Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	4
294	Antibody Responses to the SARS-CoV-2 Ancestral Strain and Omicron Variants in Moderna mRNA-1273 Vaccinated Active-Duty US Navy Sailors and Marines. <i>Journal of Infectious Diseases</i> , 2023, 228, 149-159.	1.9	3
295	Variants of SARS-CoV-2: Influences on the Vaccines™ Effectiveness and Possible Strategies to Overcome Their Consequences. <i>Medicina (Lithuania)</i> , 2023, 59, 507.	0.8	5
296	Reduced neutralizing antibody response to SARS-CoV-2 vaccine booster dose in people living with HIV with severe immunosuppression. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	5
298	Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants. <i>Npj Vaccines</i> , 2023, 8, .	2.9	7
300	Persistent SARS-CoV-2-specific immune defects in kidney transplant recipients following third mRNA vaccine dose. <i>American Journal of Transplantation</i> , 2023, 23, 744-758.	2.6	8
301	Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain. <i>Nature Communications</i> , 2023, 14, .	5.8	6
302	Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial. <i>ELife</i> , 0, 12, .	2.8	6
303	The Effect of the Immunization Schedule and Antibody Levels (Anti-S) on the Risk of SARS-CoV-2 Infection in a Large Cohort of Healthcare Workers in Northern Italy. <i>Vaccines</i> , 2023, 11, 746.	2.1	4
304	Exploring the Potential of Broadly Neutralizing Antibodies for Treating SARS-CoV-2 Variants of Global Concern in 2023: A Comprehensive Clinical Review. <i>Cureus</i> , 2023, , .	0.2	1
305	Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations. <i>Multiple Sclerosis Journal</i> , 2023, 29, 884-888.	1.4	2
306	Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes. <i>Vaccine</i> , 2023, 41, 3003-3010.	1.7	1
307	Booster with Ad26.COVS.2 or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques. <i>Nature Communications</i> , 2023, 14, .	5.8	10
308	The protective nasal boosting of a triple-RBD subunit vaccine against SARS-CoV-2 following inactivated virus vaccination. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	3

#	ARTICLE	IF	CITATIONS
309	Structural basis of spike RBM-specific human antibodies counteracting broad SARS-CoV-2 variants. <i>Communications Biology</i> , 2023, 6, .	2.0	0
310	Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants. <i>Nature Communications</i> , 2023, 14, .	5.8	12
334	Effectiveness of inactivated COVID-19 vaccine against the severity of Omicron variant. <i>Frontiers of Medicine</i> , 0, , .	1.5	0
335	Long-Term Vaccination and Treatment Strategies for COVID-19 Disease and Future Coronavirus Pandemics. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 27-49.	0.8	0
340	The role of vaccines in the COVID-19 pandemic: what have we learned?. <i>Seminars in Immunopathology</i> , 0, , .	2.8	13
367	B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity. , 2024, 21, 144-158.		4